Zevra Therapeutics, Inc. Common Stock
ZVRAZevra Therapeutics, Inc. (ZVRA) is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders. The company aims to create innovative treatments by leveraging its expertise in neuropharmacology, targeting unmet medical needs in areas such as movement disorders and pain management.
Company News
XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and pot...
Zevra Therapeutics announced granting options to purchase 38,000 shares of common stock to two new employees under its 2023 Employment Inducement Award Plan, with options vesting over four years.
Zevra Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, strengthening its balance sheet and supporting its strategic priorities.
Zevra Therapeutics is consolidating its development and scientific functions under the Chief Medical Officer, resulting in the departure of the Chief Development Officer and Chief Scientific Officer. The company is also discontinuing its in-house drug discovery activities and closing its laboratory facilities to focus on late-stage clinical devel...
Zevra Therapeutics announced the commercial availability of MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C. The company's comprehensive patient support program, AmplifyAssist, is in place to address access barriers.
